This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Collaborative Wilms Tumour Africa Project

This study is currently recruiting participants.
See Contacts and Locations
Verified November 2016 by Trijn Israels, VU University Medical Center
Information provided by (Responsible Party):
Trijn Israels, VU University Medical Center Identifier:
First received: November 12, 2013
Last updated: November 14, 2016
Last verified: November 2016

Significant progress has been made in the treatment of Wilms tumor in high income countries, where survival is now around 85% - 90%. Survival in low income countries is much lower; specific challenges include late presentation, malnutrition, less intense supportive care facilities and failure to complete treatment.

A comprehensive treatment guideline was introduced in Malawi in 2006 which included nutritional support and social support to enable parents to complete treatment. Survival has increased to around 50%; 95% of children completed their treatment. A multi-disciplinary group of African clinicians and 'state of the art' experts produced a consensus treatment guideline for children with Wilms tumor in sub-Saharan Africa. This guideline will be implemented as a multi-center prospective clinical trial in 2014 in six - eight institutes, expecting about 200 new patients per year.

The hypothesis is that 2 year event free survival will be 50%, with <10% failure to complete treatment and <10% treatment related mortality. Other research questions include efficacy and toxicity of preoperative chemotherapy and the comparison of surgical staging, local pathology and central review pathology in stratifying postoperative chemotherapy.

Condition Phase
Wilms Tumour Phase 4

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Collaborative Wilms Tumour Africa Project

Resource links provided by NLM:

Further study details as provided by Trijn Israels, VU University Medical Center:

Primary Outcome Measures:
  • Event free survival [ Time Frame: 2 years ]

Estimated Enrollment: 400
Study Start Date: January 2014
Estimated Study Completion Date: December 2019
Estimated Primary Completion Date: December 2017 (Final data collection date for primary outcome measure)
Wilms tumour

Children diagnosed with a Wilms tumour receive SIOP PODC Wilms tumour treatment; preoperative chemotherapy, surgery and postoperative chemotherapy (= standard care).

One group of patients.

Detailed Description:
Patients are treated according to standard care. Data are documented on presentation at diagnosis, response of the tumor, findings at surgery and pathology, treatment given and outcome of the patients.

Ages Eligible for Study:   up to 18 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Children (< 18 years) diagnosed with a Willms tumour

Inclusion Criteria:

  • Age < 18 years
  • Diagnosis Wilms tumour

Exclusion Criteria:

* None

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01991652

Contact: Trijn Israels, MD PhD +31.6.42717920
Contact: Elizabeth Molyneux, Prof

Mbingo Mission Hospital Recruiting
North West Cameroon, Cameroon
Contact: Peter Hesseling   
Principal Investigator: Francine Kouya, MD         
Tikur Anbessa Specialized Hospital Recruiting
Addis Abeba, Ethiopia
Contact: Haileyesus David, MD   
Principal Investigator: Yasar Celiker, MD         
Korle Bu Hospital Recruiting
Accra, Ghana
Contact: Lorna Renner, MD   
Principal Investigator: Lorna Renner, MD         
College of Medicine Recruiting
Blantyre, Malawi
Contact: Elizabeth Molyneux, Prof   
Contact: Neil Kennedy, Prof   
Principal Investigator: Elizabeth Molyneux, Prof         
Sponsors and Collaborators
VU University Medical Center
Study Chair: Trijn Israels, MD PhD VU University Medical Center
  More Information

Responsible Party: Trijn Israels, Paediatric Oncologist, MD PhD, VU University Medical Center Identifier: NCT01991652     History of Changes
Other Study ID Numbers: CollabWilmsAfrica
Study First Received: November 12, 2013
Last Updated: November 14, 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Keywords provided by Trijn Israels, VU University Medical Center:
Wilms tumour
Childhood cancer

Additional relevant MeSH terms:
Wilms Tumor
Neoplasms, Complex and Mixed
Neoplasms by Histologic Type
Kidney Neoplasms
Urologic Neoplasms
Urogenital Neoplasms
Neoplasms by Site
Neoplastic Syndromes, Hereditary
Kidney Diseases
Urologic Diseases
Genetic Diseases, Inborn processed this record on August 18, 2017